Markl Baum News Today

Harrow, Inc. (NASDAQ:HROW – Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 4,980,000 shares, a decline of 9.5% from the April 30th total of 5,500,000 shares. Based on an average daily volume of 510,400 shares, the […]

Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) traded down 5.8% on Wednesday . The company traded as low as $17.45 and last traded at $17.49. 215,167 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 464,695 shares. The stock had previously closed at $18.56. Analyst Upgrades […]

Harrow, Inc. (NASDAQ:HROW – Free Report) – B. Riley dropped their Q2 2024 earnings per share (EPS) estimates for Harrow in a research report issued to clients and investors on Tuesday, May 14th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.25) per share for the quarter, down from their previous […]

Harrow, Inc. (NASDAQ:HROW – Get Free Report) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 5,500,000 shares, a decrease of 7.1% from the April 15th total of 5,920,000 shares. Based on an average daily trading volume, of 462,100 shares, the days-to-cover ratio […]

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) CEO Mark L. Baum acquired 9,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $11.59 per share, for a total transaction of $104,310.00. Following the completion of the acquisition, the chief executive officer now […]

Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.

Vevye® (cyclosporine ophthalmic soln) 0.1% is a preservative-free prescription medication using proprietary water-free technology.

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 4,890,000 shares, a decline of 20.0% from the November 15th total of 6,110,000 shares. Based on an average daily trading volume, of 682,900 shares, the days-to-cover […]

Private Capital Management LLC decreased its holdings in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,152,346 shares of the company’s stock after selling 13,375 shares during the quarter. Harrow Health accounts for approximately […]

Prelude Capital Management LLC boosted its stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 6.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,456 shares of the company’s stock after purchasing an additional 2,753 shares during the quarter. Prelude Capital Management LLC […]